- Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., . . . Morris, V. K. (2023). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAFV600E</i>-mutant mCRC. Future Oncology. https://doi.org/10.2217/fon-2022-1249
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
on 18 de desembre de 2023
with No hi ha comentaris
Deixa un comentari